title: Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV.
abstract: Abnormal liver enzymes (LE) are common in patients infected with the human immunodeficiency virus (HIV) even in the absence of viral hepatitis or alcohol abuse. With availability of antiretroviral combination therapy, life expectancy has improved dramatically and as a consequence the spectrum of liver disease is changing. Increased reports on the development of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in HIV coinfected patients raise questions around prevalence, clinical manifestations, and clinical outcome of these liver diseases in HIV coinfection. Moreover, the potential impact of combination antiretroviral therapy as well as direct HIV effects on the emergence of non-alcoholic fatty liver disease needs to be explored. This review summarizes the recent literature on NAFLD and NASH in HIV.
authors.affiliation: Department of Medicine I, University Hospital Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany. juergen.rockstroh@ukb.uni-bonn.de.|German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany. juergen.rockstroh@ukb.uni-bonn.de.
authors.forename: Jürgen Kurt
authors.initials: JK
authors.lastname: Rockstroh
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D005234:Fatty Liver / Q000175:diagnosis / Q000209:etiology*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications*; D015995:Prevalence
chemical_list: D019380:Anti-HIV Agents
keywords: HIV; Liver fibrosis; NAFLD; Nash